USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $0.87, $0.07 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $252.9 million versus the consensus estimate of $253.52 million.

GUIDANCE:

USANA Health Sciences sees FY2017 EPS of $3.80-$4.10, versus the consensus of $4.47. USANA Health Sciences sees FY2017 revenue of $1.04-1.07 million, versus the consensus of $1.11 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.